$4.01
+0.37 (+10.16%)
Open$3.79
Previous Close$3.64
Day High$4.72
Day Low$3.78
52W High$5.84
52W Low$1.06
Volume—
Avg Volume126.5K
Market Cap23.93M
P/E Ratio—
EPS$-15.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+977.3% upside
Current
$4.01
$4.01
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.69M | 1.69M | 1.36M |
| Net Income | 118.4K | 113.8K | 71.1K |
| Profit Margin | 7.0% | 6.8% | 5.2% |
| EBITDA | 180.1K | 185.2K | 152.7K |
| Free Cash Flow | 113.7K | 84.7K | 88.4K |
| Rev Growth | -7.6% | +15.2% | +21.3% |
| Debt/Equity | 0.66 | 0.76 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |